RecruitingNCT06502015
Neurological
Stiff Person Syndrome
Also known as SPS, stiff man syndrome, anti-GAD65 autoimmune syndrome, progressive encephalomyelitis with rigidity and myoclonus (PERM)
Stiff person syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive fluctuating muscular rigidity of the trunk and proximal limbs, with painful episodic muscle spasms triggered by emotional stress, noise, or
2
studies recruiting now
as of 7 Sept 2026
19
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
11 Feb 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Showing the 2 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Stiff Person Syndrome studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Stiff Person Syndrome study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
About Stiff Person Syndrome
Stiff person syndrome (SPS) is a rare autoimmune neurological disorder characterized by progressive fluctuating muscular rigidity of the trunk and proximal limbs, with painful episodic muscle spasms triggered by emotional stress, noise, or touch. Most patients have high-titer anti-GAD65 autoantibodies. SPS is associated with other autoimmune conditions, particularly type 1 diabetes. VGCC and glycine receptor antibodies define rarer variants. Treatment includes GABAergic medications and immunotherapy.
Common clinical features
Fluctuating trunk and limb rigidityPainful muscle spasmsExaggerated lumbar lordosisHypersensitivity to stimuliFallsAnxiety and phobiaCo-existing autoimmune conditions
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
1 approved treatment and 2 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Diazepam (Alupram 10)
Phase 2Efgartigimod Alfa (Efgartigimod alfa component of vyvgart hytrulo)
Phase 2Rituximab (Blitzima)
Before you apply
Things trial teams commonly ask about for Stiff Person Syndrome. Not eligibility rules; those are set by each study.
- Anti-GAD65 antibody titer (markedly elevated, typically >1000 IU/mL) is required for SPS diagnosis and trial eligibility
- Stiffness index measurement and surface EMG documentation of continuous motor unit firing are objective eligibility markers
- Immunotherapy trial history (IVIG, plasmapheresis, rituximab) must be documented — washout periods are required
- SPS variants (PERM with glycine receptor antibodies vs. classic anti-GAD65 SPS) may have separate trial eligibility criteria
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).